Search results
PROMOTED
How do worsening heart events dictate the long-term outcomes of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and can earlier intervention influence the disease trajectory in ATTR-CM? In this new sub-analysis from ATTRibute-CM, recorded onsite at ESC Heart Failure Congress (HFA) 2026, Prof Marianna Fontana (University College London, London, UK) sheds further light onto these…
View more
HFA 2026: Updates on ATTR-CM
Author(s):
Marianna Fontana
,
Added:
6 days ago
Video Series
ESC 25: SWEDEPAD 1 and 2
Author(s):
Marten Falkenberg
,
Joakim Nordanstig
Added:
8 months ago
Video
Author(s):
Harriette Van Spall
,
Marc P Bonaca
Added:
1 year ago
ACC 25 - STRIDE shows subcutaneous semaglutide improved walking ability and related quality of life in patients with both type 2 diabetes and peripheral arterial disease (PAD) with intermittent claudication symptoms.Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Marc Bonaca (University of Colorado School of Medicine, Aurora, CO, US) to discuss the…
View more
Author(s):
Marc P Bonaca
Added:
1 year ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,…
View more
Author(s):
Giuseppe Ferrante
,
Brittany A Bacallao
,
Francesco Gioia
,
et al
Added:
1 year ago
Author(s):
Subodh Verma
Added:
8 months ago
ESC Congress 2025 - New findings from STRIDE further demonstrate effectiveness of semaglutide in improving functional outcomes in PAD.Dr Subodh Verma joins us to discuss new findings from the STRIDE study, which investigated semaglutide 1.0mg in individuals with peripheral artery disease (PAD). 792 participants were enrolled in the trial, 24.6% of which were female, and 75.4% male.Findings showed…
View more
Author(s):
Added:
10 months ago
ADA 2025 - We are joined by Dr Alice Cheng (University of Toronto, Toronto, CA) to discuss the clinical implications of STRIDE (NCT04560998). The placebo-controlled study investigated whether semaglutide with standard-of-care treatment has an effect on walking ability in patients with PAD and T2D. The primary outcome measure was the change in maximum walking distance on a constant load treadmill…
View more
Mary McDermott
Author
Author(s):
Tobias Geisler
Added:
1 year ago
TCT 24: The SIRONA Trial
Author(s):
Ulf Teichgräber
Added:
1 year ago
Video